EU ministers call for better access to "valuable" new drugs
This article was originally published in SRA
EU ministers have called on the European Commission and member states to take steps to give patients equitable access to new, innovative medicines while ensuring that these medicines are of real added value and do not unduly burden countries' health budgets1.
You may also be interested in...
While the EU attempts to accelerate the pace of its unified approach to vaccine roll-out, some eastern European countries are taking their own decisions.
The pharmaceutical industry and other stakeholders have taken part in the launch event for a new initiative intended to tackle issues that have been amplified by the COVID-19 pandemic, such as supply chain resilience and medicine shortages. The project has drawn a mixed response from industry bodies.
The MHRA is losing no time in getting its much heralded “new era” of medicines regulation up and running.